Freenome Test
Diagnostic TestParticipants who provide informed consent, meet the eligibility criteria and provide a blood sample for this study will be enrolled.
NCT Number: NCT05516927
This protocol is a prospective, case-control multi-center diagnostic study to assess the sensitivity and specificity of blood-based screening tests for the early detection of multiple cancers.
Looking for future studies?
Notify Me30 year and older
All sexes
Observational
Crisp Regional Hospital, Cordele, Georgia, United States
Healthy volunteers accepted: Yes
Only the study team can determine whether someone qualifies for participation.
Key Inclusion Criteria:
Key Exclusion Criteria:
Participants who provide informed consent, meet the eligibility criteria and provide a blood sample for this study will be enrolled.
Time frame: 12 months
To compare blood samples from cancer case and non-cancer control subjects in order to develop and characterize blood-based multiomics tests in specific cancer types or in a combination of multiple cancers.
Freenome Holdings Inc.
Industry
The Sanderson Study: A Diagnostic Case-Control Study for the Development of Multiomics Blood Tests for Cancer Screening in a Real World Setting
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT07224854
Cell Free DNA, Colonic Diseases
Monrovia, California, United States
View Trial Details